Electric Hydrogen receives DNV validation after the respected independent engineering firm's comprehensive assessment of the company's HYPRPlant
DNV's extensive review identified risks and assessed factors that may affect HYPRPlant's performance and reliability in the field, and opined on Electric Hydrogen's efforts to mitigate them. The review also assessed the company's ability to deliver and service the plants. The report includes DNV's detailed review of electrolyzer stack technology, plant design, performance, reliability, manufacturing, quality and the standard plant's product warranty and commercial assurances for the core technology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
an hour ago
- Toronto Star
Brookfield Infrastructure Reports Solid Second Quarter 2025 Results
BROOKFIELD, News, July 31, 2025 (GLOBE NEWSWIRE) — Brookfield Infrastructure Partners L.P. (Brookfield Infrastructure, BIP, or the Partnership) (NYSE: BIP; TSX: today announced its results for the second quarter ended June 30, 2025. 'We had an active second quarter with our capital recycling strategy. We made three marquee acquisitions and also generated substantial proceeds from asset sales,' said Sam Pollock, Chief Executive Officer of Brookfield Infrastructure. 'Our ability to consistently buy high-quality assets for value and monetize mature investments at attractive returns, continues to differentiate our platform and positions us well to self-fund a growing pipeline of opportunities.'
Toronto Star
an hour ago
- Toronto Star
Voluntary TSX delisting application
TORONTO, July 31, 2025 (GLOBE NEWSWIRE) — Xanadu Mines Ltd (ASX:XAM, TSX:XAM) ACN 114 249 026 (Xanadu or the Company) refers to its previous announcement released on 29 July 2025 (Announcement) regarding the Compulsory Acquisition Notice provided by Bastion Mining Pte. Ltd. UEN 202512367N (Bastion) on 25 July 2025, pursuant to which Bastion will exercise its right to compulsorily acquire the remaining Xanadu Shares under the Corporations Act 2001 (Cth) (Compulsory Acquisition). Further to the Announcement, Xanadu provides the following update in relation to its listing on the Toronto Stock Exchange (TSX).
Toronto Star
an hour ago
- Toronto Star
XORTX Announces USD $114,500 Private Placement
CALGARY, Alberta, July 31, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces a non-brokered private placement to raise up to USD $114,500 through the issuance of up to 156,849 common share units ('Units') of the Company at a price of USD $0.73 per unit (the 'Offering'). Each Unit will be comprised of one common share and one common share purchase warrant (a 'Warrant'). Each Warrant will entitle the holder, on exercise, to purchase one additional common share in the capital of the Company, at a price of USD $1.20 per Warrant until the close of business on the day which is 60 months from the date of issuance of the Units, provided, however, that if the closing price of the common shares on the Nasdaq is greater than USD $2.00 for 10 or more consecutive trading days, the Warrants will be accelerated and the Warrants will expire on the 30th business day following the date of such notice. Allen Davidoff, CEO of XORTX stated, 'With additional interest in the LIFE offering (see news release of June 26 and July 22, 2025) from non-Canadian investors, XORTX has undertaken this small private placement to accommodate these subscribers.'
